

Drug/Class	Effective Date	Overview	Posting Requirement for Notification to Providers
8/19/2024 Retevmo	9/1/2024	Removing age limitations	5 days
Vonjo	9/1/2024	Removing age from criteria; Removing documentation requirement for platelets; Adding Ojjaara as step option with higher platelets	5 days
Jakafi	9/1/2024	Standardizing myelofibrosis (MF) criteria, Adding diagnosis to GVHD continuation criteria; Updating continuation language; Standardizing all approval durations to 1 year	5 days
Rezurock	9/1/2024	Removing age from criteria; Updating to 1 year initial approval duration	5 days
Imbruvica	9/1/2024	Adding diagnosis to cGVHD continuation criteria; Standardizing indication language	5 days
Ingrezza Sprinkle	9/1/2024	Adding to formulary with PA	5 days
Vioice Oral Granules	9/1/2024	Adding to formulary with PA	5 days
Skyrizi	9/1/2024	Adding ulcerative colitis (UC) indication	5 days
Scemblix	9/1/2024	Adding to formulary with PA	5 days

Kevzara	9/1/2024	Adding new polyarticular juvenile idiopathic arthritis (pJIA) indication	5 days
Orencia	9/1/2024	Adding Rinvoq as preferred product for polyarticular juvenile idiopathic arthritis (pJIA)	5 days
7/18/2024 Fasenra	8/1/2024	Updating age restriction to \geq 6 years following recent age expansion	5 days
Spevigo	8/1/2024	Adding to formulary with PA	5 days
Alecensa	8/1/2024	Adding adjuvant treatment indication	5 days
Rinvoq	8/1/2024	Adding indication for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers	5 days
6/20/2024 Nexletol/Nexlizet	7/1/2024	Removing PA	5 days
Repatha	7/1/2024	Removing PA	5 days
Stromectol (ivermectin) tablet	7/1/2024	Removing PA	5 days
Ergomar	1/1/2025	Adding to formulary with PA	5 days

Fanapt	7/1/2024	Adding indication for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults	5 days
Enspryng	9/1/2024	Updating criteria to not be used in combination with other biologic therapies (initial and continuation criteria); Adding diagnosis to continuation criteria	60 days
Sunosi	7/1/2024	Updating initial approval duration from the current 3-month duration to 1 year	5 days
Wakix	7/1/2024	Updating initial approval duration from the current 3-month duration to 1 year	5 days
sodium oxybate oral soln (generic Xyrem)	7/1/2024	Updating initial approval duration from the current 3-month duration to 1 year	5 days
Lumryz	7/1/2024	Updating initial approval duration from the current 3-month duration to 1 year	5 days
Augtyro	7/1/2024	Adding to formulary with PA	5 days
Fruzaqla	7/1/2024	Adding to formulary with PA	5 days
Ojjaara	7/1/2024	Adding to formulary with PA	5 days
Truqap	7/1/2024	Adding to formulary with PA	5 days
Zurzuva	7/1/2024	Adding to formulary with PA	5 days

Entyvio SC	7/1/2024	Adding to formulary with PA	5 days
5/20/2024 Adalimumab	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Cimzia	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Zeposia	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Orencia	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Olumiant	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products; Standardizing alopecia areata language	5 days
Simponi	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Kevzara	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Actemra	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Xeljanz/Xeljanz XR	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
Rinvoq	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products; Standardizing language for diagnosis of atopic dermatitis	5 days

Kineret	6/1/2024	Adding Simlandi and adalimumab-aaty to preferred list of adalimumab products	5 days
lithium oral solution	6/1/2024	Adding to formulary with PA (PA required for members age 9 years and older)	5 days
Brkinsa	6/1/2024	Adding indication for treatment of adult patients with relapsed or refractory follicular lymphoma (FL)	5 days
Livmarli	6/1/2024	Adding indication for treatment of cholestatic pruritis in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC)	5 days
Iclusig	6/1/2024	Adding indication for newly diagnosed Ph+ALL; Updating the step requirement to >= 2 alternative kinase inhibitors instead of 4 for diagnosis of chronic phase (CP) chronic myeloid leukemia (CML)	5 days
Zokinvy	6/1/2024	Adding continuation criteria	60 days
Cholbam	6/1/2024	Removing coverage of peroxisomal disorders due to lack of clinical benefit; Clarifying coverage of specific enzyme defects	60 days
Venclexta	6/1/2024	Adding coverage for induction-eligible poor-risk acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) combination with ibrutinib	5 days
Viibryd (vilazodone)	6/1/2024	Removing PA	5 days
Promacta	6/1/2024	Adding diagnosis to continuation criteria for diagnosis of chronic immune thrombocytopenia (ITP)	5 days

4/19/2024 Tremfya	5/1/2024	Standardizing diagnosis for psoriasis to continuation criteria (adding mention of palmoplantar psoriasis)	5 days
Taltz	5/1/2024	Standardizing diagnosis for psoriasis to continuation criteria (adding mention of palmoplantar psoriasis)	5 days
Skyrizi	5/1/2024	Adding diagnosis to continuation criteria for plaque psoriasis	5 days
Stelara	5/1/2024	Adding diagnosis to continuation criteria for plaque psoriasis	5 days
Otezla	5/1/2024	Adding diagnosis to continuation criteria	5 days
Xolair	5/1/2024	Adding food allergy indication	5 days
Tagrisso tab	5/1/2024	Adding indication for EGFR-mutated locally advanced or metastatic NSCLC in combo therapy	5 days
Sogroya	5/1/2024	Removing daily somatropin step in adult patients	5 days
3/18/2024 Bosulif cap	3/1/2024	Adding to formulary with PA	5 days
Hyqvia inj	4/1/2024	Adding indication for chronic inflammatory demyelinating polyneuropathy (CIDP)	5 days
Balversa	6/1/2024	Updating indication and criteria related to full FDA-approval and updated guidelines	60 days

Dupixent	4/1/2024	Updating age and weight for eosinophilic esophagitis (EoE) based on indication expansion; Standardizing atopic dermatitis language	5 days
Ubrelyv	4/1/2024	Updating step therapy requirements from trial of triptan plus NSAID combination therapy plus an additional triptan trial to trial of two triptans	5 days
Reyvow	4/1/2024	Updating step therapy requirements from trial of triptan plus NSAID combination therapy plus an additional triptan trial to trial of two triptans	5 days
Zavzpret nasal spray	4/1/2024	Updating step therapy requirements from trial of triptan plus NSAID combination therapy plus an additional triptan trial to trial of two triptans	5 days
Veltassa powder	6/1/2024	Adding age limitations to PA criteria, based on FDA-approved indication	60 days
Lokelma packet for oral suspension	6/1/2024	Adding age limitation to PA criteria	60 days
Litfulo	4/1/2024	Adding to formulary with PA	5 days
Sohonos	4/1/2024	Adding to formulary with PA	5 days
Vanflyta	4/1/2024	Adding to formulary with PA	5 days
Balversa	4/1/2024	Removing mutation documentation requirement	5 days

Vitrakvi	4/1/2024	Removing mutation documentation requirement	5 days
Xospata	4/1/2024	Removing mutation documentation requirement	5 days
Iressa	4/1/2024	Removing mutation documentation requirement	5 days
Lorbrena	4/1/2024	Removing mutation documentation requirement	5 days
Stivarga	4/1/2024	Removing mutation documentation requirement	5 days
Tepmetko	4/1/2024	Removing mutation documentation requirement	5 days
Alecensa	4/1/2024	Removing mutation documentation requirement	5 days
Alunbrig	4/1/2024	Removing mutation documentation requirement	5 days
Ayvakit	4/1/2024	Removing mutation documentation requirement	5 days
Gavreto	4/1/2024	Removing mutation documentation requirement	5 days
Gilotrif	4/1/2024	Removing mutation documentation requirement	5 days

Iclusig	4/1/2024	Removing mutation documentation requirement	5 days
Idhifa	4/1/2024	Removing mutation documentation requirement	5 days
Krazati	4/1/2024	Removing mutation documentation requirement	5 days
Lonsurf	4/1/2024	Removing mutation documentation requirement	5 days
Lumakras	4/1/2024	Removing mutation documentation requirement	5 days
Lynparza	4/1/2024	Removing mutation documentation requirement	5 days
Orserdu	4/1/2024	Removing mutation documentation requirement	5 days
Pemazyre	4/1/2024	Removing mutation documentation requirement	5 days
Piqray	4/1/2024	Removing mutation documentation requirement	5 days
Retevmo	4/1/2024	Removing mutation documentation requirement	5 days
Rezlidhia	4/1/2024	Removing mutation documentation requirement	5 days

Rydapt	4/1/2024	Removing mutation documentation requirement	5 days
Tabrecta	4/1/2024	Removing mutation documentation requirement	5 days
Tafinlar	4/1/2024	Removing mutation documentation requirement	5 days
Mekinist	4/1/2024	Removing mutation documentation requirement	5 days
Tagrisso	4/1/2024	Removing mutation documentation requirement	5 days
Talzenna 0.25 mg, 0.5 mg, 0.75 mg, 1 mg	4/1/2024	Removing mutation documentation requirement	5 days
Xalkori	4/1/2024	Removing mutation documentation requirement	5 days
Zelboraf	4/1/2024	Removing mutation documentation requirement	5 days
Cotellic	4/1/2024	Removing mutation documentation requirement	5 days
Zykadia	4/1/2024	Removing mutation documentation requirement	5 days
2/16/2024 Xphozah	3/1/2024	Adding to formulary with PA	5 days

Jaypirca	5/1/2024	Adding indication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); Adding requirement of two (2) prior lines of systemic therapy, which should include a covalent BTK inhibitor and a BCL-2 inhibitor to match FDA approval language	60 days
Nexletol/Nexlizet	3/1/2024	Updating criteria to reflect indication expansion	5 days
Adbry	3/1/2024	Adding diagnosis to continuation criteria	5 days
Welireg	3/1/2024	Adding criteria for advanced renal cell carcinoma (RCC)	5 days
Evrysdi	3/1/2024	Adding coverage of presymptomatic spinal muscular atrophy (SMA)	5 days
Copiktra cap	5/1/2024	Removing follicular lymphoma indication	60 days
Banzel susp (rufinamide susp/tab)	3/1/2024	Including new treatment guideline; Changing approval duration to lifetime from 1 year	5 days
Cinryze	5/1/2024	Updating criteria to exclude any combination prophylaxis use	60 days
Haegarda	5/1/2024	Updating criteria to exclude any combination prophylaxis use	60 days
Berinert	5/1/2024	Updating criteria to exclude any combination prophylaxis use	60 days

Ruconest	5/1/2024	Updating criteria to exclude any combination prophylaxis use	60 days
Takhzyro	5/1/2024	Updating criteria to exclude any combination prophylaxis use	60 days
Thalomid	3/1/2024	Removing PA	5 days
12/18/2023 Zavzpret	1/1/2024	Adding to formulary with PA	5 days
Skytrofa	1/1/2024	Removing step requirement	5 days
Sogroya	1/1/2024	Adding to formulary with PA	5 days
Vowst	1/1/2024	Adding to formulary with PA	5 days
Veozah	1/1/2024	Adding to formulary with PA	5 days
Hizentra	1/1/2024	Updating initial approval duration to 1 year for diagnosis of chronic inflammatory demyelinating polyneuropathy	5 days
Uceris	1/1/2024	Updating approval duration to 1 year	5 days
Nucala	1/1/2024	Updating initial approval durations to 1 year	5 days

Xolair	1/1/2024	Updating initial approval durations to 1 year	5 days
Cimzia	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis	5 days
Stelara	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis and ulcerative colitis	5 days
Zeposia	1/1/2024	Updating initial approval duration to 1 year for diagnosis of ulcerative colitis	5 days
Humira biosimilars (adalimumab-adaz, adalimumab-fkjp, Hadlima), Humira	1/1/2024	Updating initial approval duration to 1 year for diagnosis of ulcerative colitis, plaque psoriasis, Hidradenitis suppurativa	5 days
Kineret	1/1/2024	Updating initial approval durations to 1 year	5 days
Otezla	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis and oral ulcers associated with Behcet's disease	5 days
Olumiant	1/1/2024	Updating initial approval duration to 1 year for diagnosis of alopecia areata	5 days
Enbrel	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis	5 days
Simponi subq	1/1/2024	Updating initial approval duration to 1 year	5 days

Xeljanz	1/1/2024	Updating initial approval duration to 1 year for diagnosis of ulcerative colitis	5 days
Rinvoq	1/1/2024	Updating initial approval duration to 1 year for diagnosis of atopic dermatitis and ulcerative colitis	5 days
Empaveli	1/1/2024	Updating initial approval duration to 1 year	5 days
Dupixent	1/1/2024	Updating initial approval durations to 1 year	5 days
Tremfya	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis	5 days
Taltz	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis	5 days
Skyrizi subq	1/1/2024	Updating initial approval duration to 1 year for diagnosis of plaque psoriasis	5 days
Zoryve	1/1/2024	Updating initial approval duration to 1 year	5 days
Opzelura	1/1/2024	Updating initial approval duration to 1 year for diagnosis of nonsegmental vitiligo	5 days
Benlysta	1/1/2024	Updating initial approval duration to 1 year for diagnosis of active lupus nephritis	5 days
Enspryng	1/1/2024	Updating initial approval duration to 1 year	5 days

11/16/2023 Ezallor Sprinkle	12/1/2023	Adding to formulary with PA (PA required for members age 9 years or older)	5 days
Mekinist oral solution	12/1/2023	Adding to formulary with PA	5 days
Tafinlar tab for oral suspension	12/1/2023	Adding to formulary with PA	5 days
Omnitrope	12/1/2023	Adding to formulary with PA	5 days
Hemlibra	12/1/2023	Removing step through factor products	5 days
Galafold	2/1/2024	Updating PA criteria for consistency with enzyme replacement products (diagnostic confirmation, no combination use, adding continuation criteria)	60 days
Nucala	3/1/2024	Adding indications to continuation criteria	5 days
Tezspire	3/1/2024	Adding indication to continuation criteria	5 days
10/18/2023 Nexlizet	11/1/2023	Removing ezetimibe step requirement	5 days
Nexletol	11/1/2023	Removing ezetimibe step requirement	5 days
Ingrezza	11/1/2023	Adding initiation pack to formulary with PA, Adding indication of chorea associated with Huntington's disease, Adding diagnosis to continuation criteria	5 days

Prevymis	11/1/2023	Updating approval duration for post-HSCT to 200 days	5 days
Nitrofurantoin	11/1/2023	Updating PA form to only list the 25 mg strength in the "indicate medication requested" section	5 days
Lonsurf	11/1/2023	Adding continuation criteria, Adding indication for use with bevacizumab	5 days
9/21/2023 Austedo XR tab titration pack	10/1/2023	Adding to formulary with PA	5 days
Lumryz	10/1/2023	Adding to formulary with PA	5 days
Bylvay	10/1/2023	Adding indication for Alagille syndrome	5 days
Lynparza	10/1/2023	Adding indication of mCRPC for combination use with abiraterone plus steroid	5 days
Gavreto	12/1/2023	Removing medullary thyroid cancer indication (withdrawn)	60 days
Alkindi granules	10/1/2023	Removing age requirements from PA form language	5 days
Atorvaliq susp	10/1/2023	Removing age requirements from PA form language	5 days

Eprontia soln	10/1/2023	Removing age requirements from PA form language	5 days
Flolipid soln	10/1/2023	Removing age requirements from PA form language	5 days
Revatio susp	10/1/2023	Removing age requirements from PA form language	5 days
Xatmep soln	10/1/2023	Removing age requirements from PA form language	5 days
Zonisade susp	10/1/2023	Removing age requirements from PA form language	5 days
clobazam susp	10/1/2023	Removing age requirements from PA form language	5 days
Norliqva oral soln	10/1/2023	Removing age requirements from PA form language	5 days
Orserdu	10/1/2023	Adding to formulary with PA	5 days
Skyclarlys	10/1/2023	Adding to formulary with PA	5 days
Jaypirca	10/1/2023	Adding to formulary with PA	5 days
Joenja	10/1/2023	Adding to formulary with PA	5 days

Daybue	10/1/2023	Adding to formulary with PA	5 days
Filspari	10/1/2023	Adding to formulary with PA	5 days
Hadlima (Humira biosimilar)	10/1/2023	Adding to formulary with PA	5 days
adalimumab-adaz (Humira biosimilar)	10/1/2023	Adding to formulary with PA	5 days
adalimumab-fkjp (Humira biosimilar)	10/1/2023	Adding to formulary with PA	5 days
Cimzia	10/1/2023	Updating preferred adalimumab products	5 days
Zeposia	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
Orencia	10/1/2023	Updating preferred adalimumab products	5 days
Olumiant	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
Simponi auto-injector 100 mg / injection 100 mg	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
Kevzara	10/1/2023	Updating preferred adalimumab products	5 days

Actemra actpen inj / sc inj	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
Xeljanz / Xeljanz XR	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
Rinvoq	10/1/2023	Updating preferred adalimumab products, Adding diagnosis to continuation criteria	5 days
8/21/2023 Linzess	9/1/2023	Adding indication of functional constipation (FC) in pediatric patients aged 6 to 17 years	5 days
Prevymis tab	9/1/2023	Adding indication for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV+/recipient CMV-)	5 days
Ayvakit	9/1/2023	Adding indication for the treatment of adult patients with indolent systemic mastocytosis (ISM)	5 days
Austedo/XR tab	9/1/2023	Adding the XR formulation to formulary with PA, Removing tetrabenazine (Xenazine) step for diagnosis of chorea associated with Huntington's disease	5 days
Radicava ORS/Starter Kit	9/1/2023	Changing FVC criterion to $\geq 60\%$	5 days
lapatinib (generic Tykerb)	9/1/2023	Adding oncology continuation criteria	5 days
Opzelura	9/1/2023	Adding allergist and immunologist to allowable specialists for diagnosis of atopic dermatitis	5 days

Zeposia/Starter Pack	9/1/2023	Updating step through agents for diagnosis of ulcerative colitis	5 days
Zejula	11/1/2023	Adding the tablet formulation to formulary with PA, Removing late-line treatment indication (withdrawn), Removing capsule quantity limit (QL) question	60 days
Lynparza	11/1/2023	Removing late-line treatment indication (withdrawn)	60 days
7/18/2023 Rinvoq	8/1/2023	Adding indication of Crohn's disease	5 days
Cimzia	10/1/2023	Updating step through criteria for Crohn's disease indication	60 days
Lumakras	10/1/2023	Updating criteria to include "has not experienced disease progression on a <i>KRAS</i> G12C inhibitor"	60 days
Epidiolex	8/1/2023	Updating criteria to include "or in consultation with" for prescriber specialty; Separating criteria into initial and continuation criteria	5 days
Diacomit	8/1/2023	Updating criteria to include "or in consultation with" for prescriber specialty	5 days
6/16/2023 Strensiq	9/1/2023	Limiting initial approvals to 6 months, and 1 year on continuation approvals. Previous approval length was lifetime	60 days
Kevzara	7/1/2023	Adding indication for the treatment of polymyalgia rheumatica (PMR)	5 days

Imbruvica tab (420 mg, 560 mg), cap (70 mg, 140 mg), susp	9/1/2023	Removing withdrawn indications of mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL)	60 days
Trikafta granules	7/1/2023	Adding to formulary with PA	5 days
Trikafta tab	7/1/2023	Updating age requirements down to 2 years old	5 days
Lytgobi	7/1/2023	Adding to formulary with PA	5 days
Krazati	7/1/2023	Adding to formulary with PA	5 days
Rezlidhia	7/1/2023	Adding to formulary with PA	5 days
Relyvrio	7/1/2023	Adding to formulary with PA	5 days
Nexletol	7/1/2023	Adding to formulary with PA	5 days
Nexlizet	7/1/2023	Adding to formulary with PA	5 days
5/17/2023 Votrient	6/1/2023	Removing age criteria	5 days
FloLipid	6/1/2023	Adding to formulary with PA (PA required for members age 9 years or older)	5 days

Atorvaliq	6/1/2023	Adding to formulary with PA (PA required for members age 9 years or older)	5 days
Tezspire (pen)	6/1/2023	Adding to formulary with PA	5 days
Cibinqo	6/1/2023	Updating age criteria - expanding age to 12 and older	5 days
Tafinlar	6/1/2023	Adding new indication of low-grade glioma	5 days
Mekinist	6/1/2023	Adding new indication of low-grade glioma	5 days
Strensiq	6/1/2023	Adding continuation criteria	5 days
4/20/2023 lubiprostone (generic Amitiza)	5/1/2023	Adding to formulary with PA	5 days
Purixan	5/1/2023	Adding to formulary with PA (PA required for members age 9 years or older)	5 days
Aimovig	5/1/2023	Updating criteria related to concurrent use with any botulinum toxin product	5 days
Ajovy	5/1/2023	Updating criteria related to concurrent use with any botulinum toxin product	5 days
Emgality	5/1/2023	Updating criteria related to concurrent use with any botulinum toxin product	5 days

Linzess	7/1/2023	Adding generic lubiprostone step requirement	60 days
Vyndaqel	5/1/2023	Updating diagnostic criteria requirements	5 days
Vyndamax	5/1/2023	Updating diagnostic criteria requirements	5 days
3/22/2023 Tukysa	4/1/2023	Adding new indication for colorectal cancer	5 days
Brkinsa	4/1/2023	Adding new indication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)	5 days
Epiduo (adapalene/benzoyl peroxide) 0.1-2.5% gel, adapalene/benzoyl peroxide gel 0.3-2.5% gel	4/1/2023	Removing PA	5 days
benznidazole	4/1/2023	Removing PA	5 days
Amjevita (adalimumab biosimilar) / Humira	4/1/2023	Adding Amjevita (adalimumab biosimilar) to the formulary with PA; Adding Amjevita to the Humira PA form	5 days
Cimzia	4/1/2023	Adding Amjevita (adalimumab biosimilar) for any indications where Cimzia steps through adalimumab with its addition to the formulary	5 days
Zeposia	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days

Orencia	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Olumiant	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Simponi 100 mg	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Kevzara	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Actemra subq injection	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Xeljanz	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Rinvoq	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary	5 days
Continuous Glucose Monitors (Dexcom G6, FreeStyle Libre)	4/1/2023	Removing PA (moving to Step Therapy)	5 days
Kisqali	4/1/2023	Adding to formulary with PA	5 days
Verzenio	4/1/2023	Updating criteria defining high-risk for early breast cancer indication	5 days
Hyftor	4/1/2023	Adding to formulary with PA	5 days

Zoryve	4/1/2023	Adding to formulary with PA	5 days
2/20/2023 Repatha	3/1/2023	Streamlining diagnostic criteria and step requirements	5 days
1/24/2023 sildenafil susp	2/1/2023	Adding to formulary with PA	5 days
REVATIO susp	2/1/2023	Adding to formulary with PA	5 days
Rinvoq	2/1/2023	Adding new indication for the treatment of adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy	5 days
Dupixent	2/1/2023	Adding new indication for the treatment of adult patients with prurigo nodularis	5 days
Cotellic	2/1/2023	Adding new indication for the treatment of adult patients with histiocytic neoplasms	5 days
Actemra	2/1/2023	Removing methotrexate and steroid steps for giant cell arteritis	5 days
12/16/2022 DESCOVY TAB	1/1/2023	Add criterion for severe adverse event other than bone or renal AE	5 Days
OFEV CAP	3/1/2023	Adding step through pirfenidone	60 Days

SOLIQUA INJ	1/1/2023	Removing PA	5 Days
XULTOPHY INJ	1/1/2023	Removing PA	5 Days
CAMZYOS CAP	1/1/2023	Adding to formulary with PA	5 Days
RADICAVA ORS STARTER KIT	1/1/2023	Adding to formulary with PA	5 Days
RADICAVA ORS SUSP	1/1/2023	Adding to formulary with PA	5 Days
ZTALMY SUSP	1/1/2023	Adding to formulary with PA	5 Days
11/18/2022 Linzess	2/1/2023	Updated to require trial of plecanatide (Trulance)	60 days
Tadliq	12/1/2022	Adding to formulary with PA	5 days
Zonisade	12/1/2022	Adding to formulary with PA	5 days
Orkambi	12/1/2022	Removing age requirement from PA form	5 days
Imbruvica (granules)	12/1/2022	Adding to formulary with PA	5 days

Pemazyre	12/1/2022	Adding new indication for myeloid/lymphoid neoplasms	5 days
Myfembree	12/1/2022	Adding new indication for endometriosis	5 days
Stelara	12/1/2022	Updating weight requirements	5 days
Retevmo	12/1/2022	Adding new indication for solid tumors and updating the indication for NSCLC	5 days
Promacta	2/1/2023	Updating prescriber requirement for immune thrombocytopenia	60 days
Esbriet	12/1/2022	Updating diagnosis criteria to allow use of transbronchial lung cryobiopsy	5 days
10/21/2022 Opzelura	11/1/2022	Adding new indication to PA form for the topical treatment of nonsegmental vitiligo	5 days
Nubeqa	11/1/2022	Adding new indication to PA form for the treatment of metastatic hormone-sensitive prostate cancer	5 days
Strensiq	1/1/2023	Updating PA criteria to require additional documentation to support diagnosis	60 days
Benlysta	11/1/2022	Updating PA criteria to remove the requirement of corticosteroids use and to better align with guidelines	5 days
Braftovi/Mektovi	11/1/2022	Updating PA criteria to align with NCCN guidelines	5 days

09/20/2022 Livtency	10/1/2022	Adding to formulary with PA	5 days
Pyrukynd	10/1/2022	Adding to formulary with PA	5 days
Vonjo	10/1/2022	Adding to formulary with PA	5 days
Dupixent	10/1/2022	Removing level of severity requirement from Atopic Dermatitis PA criteria, updating Asthma PA criteria to align with guidelines on controller medications, and adding Eosinophilic Esophagitis indication to PA form	5 days
Adbry	10/1/2022	Adding to formulary with PA	5 days
Rinvoq	10/1/2022	Removing level of severity requirement from Atopic Dermatitis PA criteria	5 days
Cibinqo	10/1/2022	Adding to formulary with PA	5 days
Xolair	10/1/2022	Updating Asthma PA criteria to align with guidelines on controller medications	5 days
Nucala	10/1/2022	Updating Asthma PA criteria to align with guidelines on controller medications	5 days
Fasenra	10/1/2022	Updating Asthma PA criteria to align with guidelines on controller medications	5 days

09/01/2022 Freestyle Libre 3 Sensor	10/1/2022	Adding to formulary with PA	5 days
Olumiant	10/1/2022	Adding new strength to formulary with PA and adding indication for Alopecia Areata to PA form	5 days
Xalkori	9/15/2022	Adding new indication for Inflammatory Myofibroblastic Tumor (IMT) to PA form	5 days
Genotropin - Adult	10/1/2022	Updating PA form to align with guidelines, removing age requirement for short bowel syndrome, and removing adherence criterion	5 days
Genotropin - Pediatric	10/1/2022	Updating PA form to align with guidelines and removing adherence criterion	5 days
08/11/2022 Stelara	9/1/2022	Updating PA form for Ulcerative Colitis continuation criteria to account for IV formulation	5 days
Toviaz (fesoterodine)	9/1/2022	Removing PA	5 days
Nevirapine ER	9/1/2022	Removing Step Therapy requirement	5 days
Tyvaso	9/1/2022	Adding to the formulary with PA	5 days
Skyrizi	9/1/2022	Adding new formulation to the formulary with PA and adding Crohn's disease indication to PA form	5 days
Imcivree	9/1/2022	Adding new indication to PA form for obesity due to Bardet-Biedl syndrome (BBS)	5 days
Tafinlar/Mekinist	9/1/2022	Adding new indication to PA form for solid tumors with the BRAF V600E mutation	5 days
CGMs (Dexcom, Freestyle Libre)	9/1/2022	Removing three provider attestation-related criteria from PA form	5 days
Jynarque	9/1/2022	Updating PA criteria to align with recent guideline updates on patient age and disease progression	5 days
Xultophy	9/1/2022	Updating PA approval duration to lifetime	5 days
Soliqua	9/1/2022	Updating PA approval duration to lifetime	5 days
Nerlynx	9/1/2022	Changing 'high-risk of recurrence' PA criteria to simply a provider attestation and adding continuation PA criteria	5 days

pyrimethamine	9/1/2022	Updating PA criteria to align with guidelines, which requires use with leucovorin for certain diagnoses	5 days
Pomalyst	9/1/2022	Adding new indication to PA form for Kaposi sarcoma	5 days
Rubraca	9/1/2022	Removing withdrawn indication from PA form for recurrent BRCA mutated advanced ovarian cancer	5 days
07/13/2022 Armodafinil	8/1/2022	Removing PA	5 days
Modafinil	8/1/2022	Removing PA	5 days
Alkindi 0.5mg, 1mg	8/1/2022	Adding to the formulary with PA (if > 9 years old)	5 days
Vijoice	8/1/2022	Adding to the formulary with PA	5 days
Lyvispah	8/1/2022	Adding to the formulary with PA	5 days
Rinvoq	8/1/2022	Adding Ankylosing Spondylitis indication to PA form	5 days
Empaveli	8/1/2022	Updating PA form to clarify criteria and align with guidelines	5 days
Humira	8/1/2022	Updating Uveitis PA criteria to allow for first-line use in severe cases	5 days
Erivedge	8/1/2022	Removing step through Odomzo (sonidegib)	5 days
06/09/2022 Livmarli	7/1/2022	Adding to the formulary with PA	5 days
Skytrofa	7/1/2022	Adding to the formulary with PA	5 days
Tavneos	7/1/2022	Adding to the formulary with PA	5 days
Voxzogo	7/1/2022	Adding to the formulary with PA	5 days
Prevymis	7/1/2022	Adding to the formulary with PA	5 days
Drug/Class	Effective Date	Overview	Posting Requirement for Notification to Providers
05/25/2022 Cialis (tadalafil) 2.5mg, 5mg	7/1/2022	Replacing PA with Step Therapy requirement	5 days
Norliqva	7/1/2022	Adding to the formulary with PA (if > 9 years old)	5 days

Donepezil	7/1/2022	Removing Step Therapy requirement	5 days
<u>04/26/2022</u> Ozobax (baclofen) susp	6/1/2022	Adding to the formulary with PA (if > 9 years old)	5 days
Rinvoq	6/1/2022	Adding Ulcerative Colitis indication to PA form	5 days
Fintepla	6/1/2022	Adding Lennox-Gastaut Syndrome indication to PA form	5 days
Lynparza	6/1/2022	Adding new Breast Cancer indication to PA form	5 days
Hepatitis C Agents (sofosbuvir/velpatasvir (Epclusa equiv), ledipasvir/sofosbuvir (Harvoni equiv), Mavyret, Vosevi)	6/1/2022	Updating PA criteria to align with treatment guidelines	5 days
Humira	6/1/2022	Removing step through traditional DMARDs for Crohn's and UC indications to align with treatment guidelines	5 days
Stelara	6/1/2022	Removing step through traditional DMARDs for Crohn's and UC indications to align with treatment guidelines	5 days
Topical androgen products (Androgel, Androderm, Axiron, Testim, testosterone)	6/1/2022	Replacing lab value requirement with provider attestation on PA form	5 days
Viibryd	6/1/2022	Removing specialist requirement from PA form	5 days
Promacta	6/1/2022	Adding continuation criteria for chronic immune thrombocytopenia	5 days
Doptelet	6/1/2022	Adding continuation criteria for chronic immune thrombocytopenia	5 days
Tavalisse	6/1/2022	Adding continuation criteria for chronic immune thrombocytopenia	5 days

Corlanor	6/1/2022	Adding PA criteria for inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome	5 days
<u>03/24/2022</u> Targeted Immunomodulators for Plaque Psoriasis (Skyrizi, Stelara, Humira, Enbrel, Tremfya, Taltz)	4/1/2022*	Updating Plaque Psoriasis criteria to allow for trial of phototherapy <i>or</i> systemic agent	5 days
Otezla	4/1/2022*	Updating Plaque Psoriasis criteria to allow for trial of phototherapy <i>or</i> systemic agent and removing minimum BSA affected to allow for mild disease	5 days
Rinvoq	4/1/2022*	Adding Atopic Dermatitis indication to PA form	5 days
Afinitor (everolimus)	5/1/2022	Updating PA criteria to align with approved indications and NCCN guidelines	5 days
Onfi (clobazam) susp	5/1/2022	Adding to the formulary with PA (if > 9 years old)	5 days
Fleqsuvy (baclofen) susp	5/1/2022	New formulation replacing discontinued First-Baclofen Compounding Kits (same GPI/manufacturer)	5 days
Sporanox (itraconazole) cap	5/1/2022	Removing PA	5 days
Sporanox (itraconazole) soln	5/1/2022	Updating PA form with approved indications for oral solution	5 days
Nucala	5/1/2022	Updating PA criteria to allow for home-administration for those 6 to 11 years old	5 days
Firdapse	5/1/2022	Adding to the formulary with PA	5 days
Dupixent	6/1/2022	Adding PA criteria to restrict combination use with other targeted immunomodulators	60 days
Methyltestosterone	6/1/2022	Updating PA criteria to only allow hypogonadism diagnosis and require documentation of testosterone level	60 days
<u>03/04/2022</u> Bylvay	4/1/2022	Adding to the formulary with PA	5 days

Kerendia	4/1/2022	Adding to the formulary with PA	5 days
Rezurock	5/1/2022*	Adding to the formulary with PA (*effective date of 5/1/22 due to GPI conversion)	5 days
Ajovy	4/1/2022	Adding to the formulary with PA	5 days
Aimovig	4/1/2022	Removing specialist requirement, reducing trial from two drug classes to one, updating Botox criteria	5 days
Emgality	4/1/2022	Removing specialist requirement, reducing trial from two drug classes to one, updating Botox criteria	5 days
Opzelura	4/1/2022	Adding to the formulary with PA	5 days
Welireg	4/1/2022	Adding to the formulary with PA	5 days
Exkivity	4/1/2022	Adding to the formulary with PA	5 days
<u>02/28/2022</u> Oxbryta	4/1/2022	Adding new formulation with age expansion for use in patients aged 4 years and older	5 days
Skyrizi	4/1/2022	Adding psoriatic arthritis (PsA) indication to PA form	5 days
Orencia	4/1/2022	Adding Skyrizi as a possible alternative to step through for PsA	5 days
Cimzia	4/1/2022	Adding Skyrizi as a possible alternative to step through for PsA	5 days
Fetzima	4/1/2022	Removing prescribed by specialist requirement from PA form	5 days
Zydelig	5/1/2022	Removing 2 indications (SLL and FL) from PA form	60 days
<u>01/26/2022</u> Carbaglu	3/1/2022	Adding all approved FDA indications to PA	5 days
Asenapine	3/1/2022	Removing PA	5 days

Xifaxan 550 mg	3/1/2022	Removing PA	5 days
Xeljanz	3/1/2022	Adding indication to PA and requiring step through TNF blocker for JAK inhibitors to match FDA indication	5 days
Rinvoq	3/1/2022	Adding indication to PA and requiring step through TNF blocker for JAK inhibitors to match FDA indication	5 days
Benlysta	3/1/2022	Adding anti-smith antibodies as option to confirm SLE diagnosis	5 days
<u>12/29/2021</u> Trecator	2/1/2022	Replacing PA with RS	5 days
Eprontia	2/1/2022	Adding to the formulary with PA	5 days
Verzenio	2/1/2022	Adding indications to PA	5 days
C1-inhibitors (Berinert, Cinryze, Ruconest)	3/1/2022	Adding step through icatibant	60 days
Alinia	2/1/2022	Allowing trial of metronidazole or tinidazole	5 days
Isturisa	3/1/2022	Adding step through ketoconazole	60 days
<u>12/24/2021</u> Otezla	1/1/2022	Updating PA criteria for Behcet's disease	5 days
<u>11/12/2021</u> Acthar	1/1/2022	Adding to the formulary with PA	5 days
Dupixent	1/1/2022	Expanding indication for patients 6 years of age and older	5 days
Oriahnn	1/1/2022	Removing step through NSAID	5 days
Truseltiq	1/1/2022	Adding to the formulary with PA	5 days
Pemazyre	1/1/2022	Updating progression criteria	5 days

Empaveli	1/1/2022	Adding to the formulary with PA	5 days
Lumakras	1/1/2022	Adding to the formulary with PA	5 days
Myfembree	1/1/2022	Adding to the formulary with PA	5 days
<u>10/25/2021</u> Zeposia	1/1/2022	Adding PA to drug	70 days
<u>10/18/2021</u> ambrisentan	12/1/2021	Adding PA to drug	5 days
bosentan	12/1/2021	Adding PA to drug	5 days
Nitrofurantoin susp	12/1/2021	Adding to formulary with PA	5 days
Nucala	12/1/2021	Adding indication to PA	5 days
Cabometyx	12/1/2021	Adding indication to PA	5 days
Jakafi	12/1/2021	Adding indication to PA	5 days
miglustat	12/1/2021	Updating criteria to align with other medications for Gaucher disease type 1	5 days
Sunosi	12/1/2021	Adding indication to PA	5 days
Wakix	12/1/2021	Adding indication to PA	5 days
Xyrem	12/1/2021	Adding indication to PA	5 days
Oxervate	12/1/2021	Updating PA form to require documentation of which eye or eyes treatment is being requested	5 days
<u>9/22/2021</u> Truvada	11/1/2021	Adding to formulary with PA due to clarifications from the federal government around ACA §0 preventive coverage of HIV medications used for pre-exposure prophylaxis (PrEP)	5 days

Invega	11/1/2021	Removing PA	5 days
Brukinsa	11/15/2021	Adding indication to PA	5 days
Tibsovo	11/1/2021	Adding indication to PA	5 days
Lenvima	11/1/2021	Adding indication to PA	5 days
Signifor	11/1/2021	Adding continuation criteria; modify approval duration	5 days
Orkambi	11/1/2021	Updating continuation criteria to be consistent with other cystic fibrosis CFTR modulators	5 days
<u>9/03/2021</u> Ukoniq	10/1/2021	Adding to formulary with PA	5 days
Fotivda	10/1/2021	Adding to formulary with PA	5 days
Tepmetko	10/1/2021	Adding to formulary with PA	5 days
Zokinvy	10/1/2021	Adding to formulary with PA	5 days
Actemra	10/1/2021	Removing trial of 2 preferred medications to trial of 1 preferred medication	5 days
Orencia	12/1/2021	Adding trial of 2 preferred alternatives	70 days
Cimzia	10/1/2021	Adding Tremfya to alts for PsO, PsA, single ST (humira) for Crohns	5 days
Xeljanz	10/1/2021	Removing Xeljanz (tofacitinib) from a first-line preferred agent in ulcerative colitis to requiring a single step through a preferred agent, which is consistent with the approved indication requiring trial of a TNF inhibitor	5 days
Simponi	10/1/2021	Adding to formulary with PA	5 days
Tremfya	10/1/2021	Removing trial of 2 preferred medications to trial of 1 preferred medication	5 days

<u>8/30/2021</u> tiopronin tab (THIOLA Equiv)	10/1/2021	Adding PA to drug	5 days
VENCLEXTA TAB	10/1/2021	Updating PA form to align with FDA- approved indications	5 days
VENCLEXTA STARTER PACK	10/1/2021	Updating PA form to align with FDA- approved indications	5 days
IBRANCE CAP	10/1/2021	Updating criteria to align with Verzenio	5 days
IBRANCE TAB	10/1/2021	Updating criteria to align with Verzenio	5 days
VERZENIO TAB	10/1/2021	Updating criteria to align with Ibrance	5 days
KORLYM TAB	10/1/2021	Adding continuation criteria with 1 year approval to PA	5 days
SOLOSEC GRANULES PACKET	10/1/2021	Adding indication to PA	5 days
<u>7/19/2021</u> AYVAKIT TAB	9/1/2021	Adding indication to PA	5 days
TRIKAFTA TAB	9/1/2021	Adding expanded age indication to PA	5 days
BENLYSTA INJ	9/1/2021	Adding limit of use in combination with voclosporin to PA	5 days
BENLYSTA AUTO INJECTOR	9/1/2021	Adding limit of use in combination with voclosporin to PA	5 days
OCALIVA TAB	9/1/2021	Adding safety criteria to PA	5 days
<u>6/30/2021</u> XOLAIR SYRINGE	8/1/2021	Adding to formulary with PA	5 days
FERRIPROX	8/1/2021	Adding indication to PA	5 days
TYVASO INH SOLN	8/1/2021	Adding indication to PA	5 days

NURTEC ODT	8/1/2021	Updating PA form to clarify coverage for acute treatment	5 days
CRINONE GEL	8/1/2021	Adding indication to PA	5 days
<u>5/28/2021</u> LAMPIT TAB	7/1/2021	Adding to formulary with PA	5 days
ONGENTYS CAP	7/1/2021	Adding to formulary with PA	5 days
ORGOVYX TAB	7/1/2021	Adding to formulary with PA	5 days
LUPKYNIS CAP	7/1/2021	Adding to formulary with PA	5 days
IMCIVREE SOLN	7/1/2021	Adding to formulary with PA	5 days
GAVRETO CAP	7/1/2021	Adding to formulary with PA	5 days
<u>5/25/2021</u> VELTASSA POWDER	7/1/2021	Moving to PB and remove step through Lokelma	5 days
ACTEMRA SC INJ	7/1/2021	Add indication to PA	5 days
PRALUENT INJ	7/1/2021	Add indication to PA	5 days
REPATHA INJ	7/1/2021	Updating criteria to align with Praluent	5 days
<u>4/26/2021</u> LORBRENA	6/1/2021	Adding indication to PA	5 days
HEMLIBRA	6/1/2021	Updating criteria for patients without inhibitors	5 days
STELARA	5/1/2021	Updating criteria for cost and safety	5 days
NINLARO	6/1/2021	Updating criteria to align with guidelines	5 days
EPANED	6/1/2021	Updating criteria to remove age restriction for patients ≤ 8 years	5 days
QBRELIS	6/1/2021	Updating criteria to remove age restriction for patients ≤ 8 years	5 days
TIROSINT-SOL	6/1/2021	Adding to formulary with PA	5 days
GLOPERBA SOLN	6/1/2021	Adding to formulary with PA	5 days

BARACLUDE SOLN	6/1/2021	Adding to formulary with PA	5 days
XATMEP SOLN	6/1/2021	Adding to formulary with PA	5 days
SOTYLIZE SOLN 5MG/ML	6/1/2021	Adding to formulary with PA	5 days
KATERZIA SUSP	6/1/2021	Adding to formulary with PA	5 days
NIZATIDINE SOLN	6/1/2021	Adding to formulary with PA	5 days
FIRST BACLOFEN SUSP KIT	6/1/2021	Adding to formulary with PA	5 days
CAROSPIR SUSP	6/1/2021	Adding to formulary with PA	5 days
<u>3/15/2021</u> Tagrisso	5/1/2021	Adding indication to PA	5 days
Epidiolex	5/1/2021	Remove age restriction; align approval duration (one year)	5 days
Diacomit	5/1/2021	Remove age restriction; align approval duration (one year)	5 days
Fintepla	5/1/2021	Remove age restriction; align approval duration (one year)	5 days
Palynziq	5/1/2021	Update continuation criteria to account for new max dosing	5 days
<u>3/9/2021</u> Enspryng	4/1/2021	Adding to formulary with PA	5 days
Fintepla	4/1/2021	Adding to formulary with PA	5 days
Evrysti	4/1/2021	Adding to formulary with PA	5 days
Inqovi	4/1/2021	Adding to formulary with PA	5 days
Dojolvi	4/1/2021	Adding to formulary with PA	5 days
<u>3/2/2021</u> Xalkori	4/1/2021	New indication added	5 days
Cabometyx	4/1/2021	New indication added and conflicting criteria removed	5 days
modafinil (PROVIGIL Equiv)	4/1/2021	New indication added	5 days

Benlysta	4/1/2021	New indication added	5 days
<u>12/23/2020</u> Nucala	2/1/2021	Adding covered indication, no formulary change	5 days
Hizentra	2/1/2021	Adding covered indication, no formulary change	5 days
<u>11/23/2020</u> Humira	1/1/2021	update to criteria, no formulary change	5 days
Enbrel	1/1/2021	update to criteria, no formulary change	5 days
Rinvoq	1/1/2021	update to criteria, no formulary change	5 days
Otezla	1/1/2021	update to criteria, no formulary change	5 days
Stelara	1/1/2021	update to criteria, no formulary change	5 days
Skyrizi	1/1/2021	update to criteria, no formulary change	5 days
Taltz	1/1/2021	update to criteria, no formulary change	5 days
Cimzia	1/1/2021	Adding to formulary with PA	5 days
Orencia	1/1/2021	update to criteria, no formulary change	5 days
Xeljanz (XR)	1/1/2021	update to criteria, no formulary change	5 days
Tremfya	1/1/2021	Adding to formulary with PA	5 days
Actemra	1/1/2021	Adding to formulary with PA	5 days
Kevzara	1/1/2021	update to criteria, no formulary change	5 days
Olumiant	1/1/2021	update to criteria, no formulary change	5 days
<u>11/16/2020</u> Tabrecta	1/1/2021	update to criteria, no formulary change	5 days
Retevmo	1/1/2021	Adding to formulary with PA	5 days
Koselugo	1/1/2021	Adding to formulary with PA	5 days

Isturisa	1/1/2021	Adding to formulary with PA	5 days
Tukysa	1/1/2021	Adding to formulary with PA	5 days
Pemazyre	1/1/2021	Adding to formulary with PA	5 days
Qinlock	1/1/2021	Adding to formulary with PA	5 days
<u>9/21/2020</u> Epidiolex	11/1/2020	Adding indication to PA	5 days
Ubrelvy	11/1/2020	Adding to formulary with PA	5 days
Cosentyx	11/1/2020	Adding indication to PA	5 days
<u>9/4/2020</u> Reyvow	10/1/2020	Adding to formulary with PA	5 days
Nurtec ODT	10/1/2020	Adding to formulary with PA	5 days
Palforzia	10/1/2020	Adding to formulary with PA	5 days
Ayvakit	10/1/2020	Adding to formulary with PA	5 days
Tazverik	10/1/2020	Adding to formulary with PA	5 days
<u>8/24/2020</u> OriaHnn	10/1/2020	Adding to formulary with PA	5 days
Xpovio	10/1/2020	Adding indication to PA	5 days
Dupixent	10/1/2020	Age expansion to PA criteria	5 days
Zydelig	10/1/2020	Adding indication to PA	5 days
<u>7/27/2020</u> Orencia	8/1/2020	Double step removed; single step only required	5 days
<u>6/25/2020</u> Braftovi	8/1/2020	New indication added for colorectal cancer	5 days
Alunbrig	8/1/2020	Criteria updated to include 1st line therapy for ALK-positive metastatic NSCLC.	5 days
Zejula	8/1/2020	Criteria updated to include 1st line maintenance therapy for ovarian and related cancers	5 days

Lynparza	8/1/2020	Two new indications added for for 1st line in HRD+ ovarian and 2nd line in mCRPC	5 days
Rubraca	8/1/2020	New indication added for mCRPC with BRCA mutation following previous androgen/taxane-based chemotherapy	5 days
Imbruvica	8/1/2020	Adding indication for first line use in Waldenstrom Macroglobulinemia	5 days
<u>6/18/2020</u> Brukinsa	7/1/2020	Added to formulary with PA	5 days
Rozlytrek	7/1/2020	Added to formulary with PA	5 days
Pomalyst	7/1/2020	Added to formulary with PA	5 days
<u>6/11/2020</u> Endari	7/1/2020	Added to formulary with PA	5 days
Oxbryta	7/1/2020	Added to formulary with PA	5 days
SCIG	7/1/2020	Added to formulary with PA	5 days
Trikafta	7/1/2020	Added to formulary with PA	5 days
<u>5/15/2020</u> Ofev	06/18/2020	New Indication added to PA	5 days
<u>4/22/2020</u> Nerlynx	6/1/2020	New Indication added to PA	5 days
<u>3/11/2020</u> Clobetasol Formulations	5/1/2020	Removing PA	5 days
<u>3/03/2020</u> Nubeqa	4/1/2020	Adding to formulary with PA	5 days
Xtandi	6/1/2020	Removing from formulary ("Not Covered" & removing PA)	60 days
Erleada	6/1/2020	Removing from formulary, ("Not Covered" & removing PA)	60 days
Abiraterone	4/1/2020	Removing PA	5 days
Sunosi	4/1/2020	Adding to formulary with PA	5 days
Wakix	4/1/2020	Adding to formulary with PA	5 days
Xyrem	4/1/2020	Updating PA criteria to match class and included information on pediatric indication	5 days

Piqray	4/1/2020	Adding to formulary with PA	5 days
Vynda	4/1/2020	Adding to formulary with PA	5 days
Xpovio	4/1/2020	Adding to formulary with PA	5 days
Turalio	4/1/2020	Adding to formulary with PA	5 days
<u>2/13/2020</u> Imatinib	4/1/20	Removing PA	
Xifaxan 550 mg	5/1/20	New indication added to criteria - hepatic encephalopathy	
Sabril	4/1/20	Removing age restriction from all indications except for infantile spasms	
<u>1/31/2020</u> Bosentan/ ambrisentan	2/26/2020	Removing the PA and changing to a restriction to specialist (pulmonologist/cardiologist) edit	
Descovy	2/26/2020	PA criteria updated to include Pre-Exposure Prophylaxis of HIV infection	
Strensiq	3/24/2020	PA criteria updated to include required documentation criteria	
CGM	3/24/2020	The continuation criteria has been updated	
HCV drugs	2/26/2020	Updated PA Criteria	
Revlimid	2/26/2020	Removing the PA and changing to a restriction to specialist edit	
Trulance	4/1/2020	Adding PA for approved indications	
Motegrity	4/1/2020	Adding PA for approved indications	
Calquence	2/26/2020	PA criteria updated to remove step	
Lynparza	2/26/2020	PA criteria updated to add pancreatic cancer	
Adempas	2/26/2020	Adding additional step therapy to PA criteria	